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Background: The present survey coordinated by the French expert centres for rare pulmonary
diseases investigated French pulmonologists’ current diagnostic and therapeutic practice for
idiopathic pulmonary fibrosis (IPF).
Methods: From December 7, 2011 to February 18, 2012, all French pulmonologists (n Z 2608)
were contacted. Those who reported following up at least one IPF patient (n Z 509) were
administered a 26-item questionnaire by phone or e-mail.
Results: 509 pulmonologists (41% of responders, 20% of French pulmonologists) were involved
in the management of IPF patients. Of those, 36% discussed the cases with radiologists and pa-
thologists. Out of 406 community pulmonologists practicing outside of reference orvils de Lyon, Hoˆpital Louis Pradel, Service de pneumologie e Centre de re´fe´rence national des mal-
aude Bernard Lyon 1, F-69677 Lyon, France. Tel.: þ33 472 357 072; fax: þ33 472 357 653.
u-lyon.fr (V. Cottin).
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196 V. Cottin et al.Statement demonstrating t
The present survey is the first
national guidelines for IPF. Coo
2011 to February 18, 2012, it inv
509 pulmonologists (20% of al
resulted from multidisciplinary
be improved through the netwcompetence (e.g. expert) centres, 141 (35%) indicated referring patients to those centres. The
2011 international guidelines for IPF were known by 67% of pulmonologists involved in IPF, 84%
of whom considered them appropriate for practice. About 58% of patients were diagnosed with
mild to moderate IPF as defined by percentage predicted forced vital capacity 50% and per-
centage predicted diffusing capacity of the lung for carbon monoxide 35%. Management re-
sulted from multidisciplinary discussion in 36% of the cases. By the end of December 2011, 49%
of patients with mild to moderately severe IPF were treated with oral corticosteroids, and 27%
received no treatment.
Conclusions: Despite correct awareness of international IPF guidelines, modalities of multidis-
ciplinary discussion and of early diagnosis and management need to be improved through the
network of expert centres.
ª 2013 Published by Elsevier Ltd.he originality and clinical relevance
survey on the management of idiopathic pulmonary fibrosis (IPF) since the 2011 inter-
rdinated by the French expert centres for rare pulmonary diseases from December 7,
estigated French pulmonologists’ current diagnostic and therapeutic practice for IPF in
l French pulmonologists) involved in the management of IPF patients. Management
discussion in only 36% of the cases; 35% of physicians referred patients to expert
for IPF. Overall, this study shows that despite awareness of
y discussion and of early diagnosis and management need to
ork of expert centres.Introduction
managementwere released in 2011 [2]. Since then, newdatacentres, and 67% knew the 2011 international guidelines
international IPF guidelines, modalities of multidisciplinarIdiopathic pulmonary fibrosis (IPF) is the most common
form of chronic idiopathic interstitial pneumonia in adults.
It is a fibroproliferative, irreversible disease of unknown
cause, occurring mainly from age 60 onward and limited to
the lungs [1]. IPF is a fatal lung disease with a variable
natural history, usually gradual and progressive. Symptoms
are not specific and consist mainly in chronic exertional
dyspnoea and dry cough. Typically, inspiratory crackles are
found at lung auscultation.
The diagnosis of IPF requires exclusion of other known
causes of interstitial lung disease (ILD) and the presence of
a usual interstitial pneumonia (UIP) pattern on high-
resolution computed tomography (HRCT), or specific com-
binations of HRCT and surgical lung biopsy UIP pattern in
patients subjected to surgical lung biopsy [2]. The accuracy
of the diagnosis of IPF increases with multidisciplinary
discussion between pulmonologists, radiologists, and pa-
thologists experienced in the diagnosis of ILD [3].
Considered as an orphan disease due to the lack of
treatment with proven efficacy until very recently [4], IPF
is a rare disease whose estimated prevalence in the United
States is between 14 and 28/100,000 and estimated inci-
dence between 6.8 and 8.8/100,000 per year [5]. In France
this would theoretically translate into at least 9000 patients
affected, with a minimum of 4400 new patients per year.
As defined by the French national plan for rare diseases,
IPF diagnosis and management are coordinated in France by
a national Reference Centre (RC) and currently 9 regional
Competence Centres (CC) for rare pulmonary diseases,
which have expertise in IPF and active patient monitoring.The latest international guidelines on IPF diagnosis and
have been published on the efficacy and safety of treatments
proposed to retard the course of the disease or alleviate its
symptoms [6]. It is now acknowledged that most of these
treatments (including oral anticoagulants, ambrisentan, and
the combination of prednisone, azathioprine, and N-acetyl-
cysteine) should not be used in IPF patients because of their
lack of efficacy and/or harmful effects [7e9]. Several other
treatments targeting the mild to moderate stages of the
disease (defined as the concomitance of a forced vital ca-
pacity 50% and diffusing capacity for carbon monoxide
35% of their respective predicted value) were under
investigation in 2011e2012 [10,11].
These considerations prompted us to conduct a national
survey in order to investigate the practical modalities of IPF
diagnosis and management (including care settings and
treatment) in France, describe the actual functioning of
the IPF management network, broadly estimate the na-
tional prevalence and incidence of IPF, in particular in its
mild to moderately severe form, and assess the expecta-
tions of pulmonologists related to IPF management.Methods: organisation of the national survey
A national survey coordinated by the French national RC
and the regional CC for rare pulmonary diseases was con-
ducted between December 7, 2011 and February 18, 2012.
The 2608 pulmonologists working in metropolitan France
were asked by phone or e-mail if they were involved in the
management of at least one patient with IPF. Repeated
Figure 2 Distribution of survey participants (and of all pul-
monologists) in metropolitan France.
Management of IPF in France 197phone calls and e-mail reminders were used if needed to
maximise the response rate.
A 26-item questionnaire was then administered to pul-
monologists who declared they were following up at least
one patient with IPF. They were asked to report the type of
care settings in which they were working and the number of
IPF patients they were currently following up. The other
questions were related to the practical modalities of
diagnosis, management, and follow-up of patients with a
mildly to moderately severe form of IPF.
Descriptive statistics were performed using Excel,
Microsoft Office 2010. Incidence and prevalence were
estimated based on the number of different IPF patients
followed up per physician participating in the survey (new
patients per year for calculation of incidence, and active
files for prevalence), with corrections for the number of
participating physicians out of the total number of respi-
ratory physicians in France, by type of practice (RC or CC,




Among the 2608 French pulmonologists, 1244 (48%)
responded to the initial query. The 509 pulmonologists (41%
of responders, 20% of all French pulmonologists, evenly
distributed within France) (Figs. 1 and 2) who declared
being involved in the management of at least one patient
with IPF agreed to participate in the survey.
A majority (69%) of the survey participants worked in
hospitals (58 in the RC or the CC, 101 in other university
hospitals, and 190 in general hospitals); 116 (23%) had a
private practice and 44 (9%)had a mixed type of medical
practice (private practice þ hospital). Distribution by
clinical practice setting was not different from those in all
French pulmonologists: 59% in hospitals, 24% in private
practice, and 17% with a mixed type of medical practice.
Sixty-nine percent of participants were male, with aFigure 1 Proportion of French pulmonologists who answered
the query and who participated to the survey.median age of 49.8 years, and 31% were female with a
median age of 42.5 years.Patient attendance by care setting
A majority of IPF patients were followed up by pulmonol-
ogists working in general hospitals or in private/mixed
practice; fewer were followed up in university hospitals,
and fewer still by the RC/CC (Table 1). The distribution
among care settings of the mean number of newly diag-
nosed IPF patients seen per year had a similar pattern. This
was consistent with the rate of direct recruitment of IPF
patients (seen for the first time by a pulmonologist), which
decreased steadily from private/mixed practice to general
hospitals, university hospitals, and RC/CC.IPF incidence in France and prevalence
Extrapolation of data from this survey suggests that IPF
incidence was approximately 4.7/100,000/year and preva-
lence 8.7/100,000 in France.
Severity of the disease was reported as mild to moderate
in about 58% of patients. This proportion was higher in
private/mixed practice than in the university hospitals and
in the RC/CC (Table 1).IPF diagnosis
The IPF diagnosis algorithm defined in the international
recommendations of 2011 (Fig. 3) was known by 67% of the
493 survey participants who answered this question, 84% of
whom found it suitable for their practice. This proportion
was lower, however, among pulmonologists who worked
exclusively in private practice than among their colleagues
who worked at least part-time in a hospital (Table 2).
Table 1 Number of IPF patients currently attended per type of physician practice.








Number of IPF patients
currently attended
556 (12%) 1112 (24%) 1877 (40%) 1135 (24%) 4680 (100%)
Proportion of attended IPF
patients with mild to
moderately severe disease
261 (47%) 600 (54%) 1070 (57%) 726 (64%) 2714 (58%)
Number of IPF patients
seen per year
286 (12%) 454 (19%) 966 (41%) 665 (28%) 2371 (100%)
Direct recruitment of patients
with mild to moderate IPF per year
120 (42%) 250 (55%) 618 (64%) 665 (100%) 1653 (70%)
RC/CC, Reference Centre/Competence Centre.
198 V. Cottin et al.In most cases, the diagnosis of mildly to moderately
severe IPF was made after a multidisciplinary discussion,
with the help of a radiologist in 78% of cases, and a pathol-
ogist in 49% of cases with lung biopsy (Fig. 4). A majority
(74%) of the pulmonologists practicing outside of the RC/CC
referred their IPF patients to RC or CC (53%, including 32% of
patients referred to the RC), or to a university hospital
(47%).
Access to experienced radiologists and pathologists
working outside of the RC/CC was possible for only 37% and
34% of respiratory physicians, respectively.
Management of mild to moderate IPF
Among the pulmonologists working outside of the RC/CC,
40% declared that management of their IPF patients
was devised in cooperation with one of those centres. In
36% of cases, the management plan resulted from aFigure 3 Diagnosis algorithm for idiopathic pulmonary
fibrosis defined by the international recommendations pub-
lished in 2011. Abbreviations: CTD, connective tissue disease;
ILD, interstitial lung disease; HRCT, high-resolution computed
tomography; IPF, idiopathic pulmonary fibrosis; MDD, multi-
disciplinary discussion; UIP, usual interstitial pneumonia (From
Raghu G., et al. Am J Respir Crit Care Med 2011; 183:788e824).multidisciplinary discussion involving other pulmonologists,
radiologists, and pathologists. Management was discussed
with other pulmonologists in only 40% of cases. Fourteen
percent of pulmonologists devised the management on
their own.
Regarding the selection of pharmacological treatment,
74% of the survey participants relied on a hospital centre,
which was the RC or a CC for 60% of the physicians and a
university hospital for 40% of the physicians.
By the end of December 2011, 27% of patients with
mildly to moderately severe IPF received no treatment; 49%
were treated with oral corticosteroids (27% with cortico-
steroids alone and 22% with corticosteroids associated with
immunosuppressive therapy or N-acetyl-cysteine). Nine
percent of patients were included in a clinical trial.
Current follow-up of patients with mild to
moderate IPF
Shared care was the rule for 56% of patients with mild to
moderate IPF. Shared care involved other pulmonologists in
91% of cases and radiologists in 14% of cases.
Overall, 35% of pulmonologists followed up their pa-
tients in the context of a coordinated care network. Such
care networks were more frequently used for patients fol-
lowed up at the RC/CC and university hospitals than for
those in the other care settings (Table 3). Involvement of
general practitioners within the coordinated care networks
was lower in the RC/CC than in the other care settings
(Table 4).
Expectations and needs of pulmonologists
regarding the diagnosis and management of mild to
moderate IPF
The main expectations of the survey participants regarding
improvements that could be proposed by the RC and CC
were related to an improved cooperation between the
different stakeholders of IPF management, recommenda-
tions to facilitate early diagnosis of the disease, a definition
of the patient care trajectory, the need for a treatment
with proven efficacy in IPF, and a publication in French of
Table 2 Proportions of pulmonologists who find interna-
tional recommendations on the management of IPF suitable
for their practice.







N Z 42 86%
University hospital N Z 77 90%
General hospital N Z 108 87%
Private practice N Z 65 72%
Mixed practice N Z 22 86%
Table 3 Proportions of pulmonologists following up their
IPF patients in the context of a coordinated care network.







N Z 45 42%
University hospitals N Z 65 46%
General hospitals N Z 95 28%
Private practice N Z 44 30%
Mixed practice N Z 17 24%
Management of IPF in France 199well-described IPF diagnostic criteria and practice-oriented
management recommendations (Fig. 5).
Discussion
This survey represents the first large-scale assessment of
clinical practice patterns regarding the diagnosis and
management of IPF by respiratory physicians in a European
country, regardless of type of practice conditions. The re-
sults reflect a strong interest of French pulmonologists in
the diagnosis and management of IPF. Nearly half of them
answered the initial question regarding their involvement in
the management of IPF patients. More than 40% of the re-
spondents (representing 20% of all French pulmonologists)
attended at least one patient with IPF and volunteered to
participate in the survey despite the absence of financial or
other incentive. Their interest in IPF was reflected by
expectation of more practical recommendations on its
diagnosis and management, written in the local language,
including in particular a better definition of the patient
care pathway.
The number of IPF patients attended and the proportion
of those with a mild to moderate form of the disease
decreased steadily from private/mixed practice and gen-
eral hospitals to the RC/CC, with intermediate numbers and
proportions being reported from the university hospitals.Figure 4 Proportion of pulmonologists discussing the diag-
nosis of mild to moderately severe IPF with other specialists.Thus, the general hospital appears to be the primary care
setting for most patients newly diagnosed with IPF, with the
university hospitals and the RC/CC being ultimately
assigned the role of secondary and tertiary care settings,
respectively.
In the absence of a recommended, well-defined patient
pathway, cooperation between the pulmonologists and
others involved in IPF management seemed to vary with
local opportunities. Structured care networks were used by
only 35% of the respondents. Thus, one lesson of this survey
is that structured care networks developed by expert cen-
tres are needed and should aim to fulfil two primary ob-
jectives. First, multidisciplinary discussions should be
generalised to facilitate earlier diagnosis and make appro-
priate decisions regarding the initial treatment. Second,
care networks should be used to ensure proper manage-
ment of acute exacerbations of IPF and of progressive
worsening of symptoms, which unfortunately characterise
the course of the disease. It can further be anticipated that
care networks will steadily improve education and exper-
tise of participating physicians, as well as foster collabo-
ration and clinical research.
Regarding the treatment of IPF, the frequent use of
corticosteroids alone (27%) or in combination with immu-
nosuppressive therapy and/or N-acetyl-cysteine (none of
them being approved for IPF) (22%) must be interpreted in
light of the state of knowledge in 2011e2012. The inter-
national recommendations published in 2011 [2] were
based on a low level of evidence for most of these treat-
ments. The few studies suggesting that some improvements
could be derived from corticosteroid-based therapies wereTable 4 Proportions of pulmonologists following up their
IPF patients in the context of a coordinated care network
involving a general practitioner.







N Z 37 68%
University hospitals N Z 57 75%
General hospitals N Z 92 83%
Private practice N Z 39 79%
Mixed practice N Z 16 88%
Figure 5 Main needs expressed by the survey participants.
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with a full placebo group had been published. Accordingly,
there was a “strong” recommendation not to use those
treatments in the majority of IPF patients, but to
“consider” them in a minority prepared to accept the risk
of long-term adverse effects in the hope of “hypothetical”
improvements [9]. The IFIGENIA study [12] reported a lower
decline of forced vital capacity in patients treated with N-
acetylcysteine versus placebo, in combination with pred-
nisone and azathioprine, but did not include a full placebo
group. Results of the PANTHER trial [7], reporting an in-
crease of hospitalisation and mortality in IPF patients
treated with the triple therapy as compared with placebo,
were released several months after the end of the present
survey. On the other hand, pirfenidone, the first drug with
efficacy demonstrated in phase III trials in the treatment of
patients with mild to moderate IPF (i.e. with forced vital
capacity 50% and carbon monoxide transfer capacity
35% of predicted value) [6,13], was granted a marketing
authorisation just at the end of the survey (February 2012)
and became available in France in October 2012. Pirfeni-
done was therefore not yet commercially available in
France when the present survey was conducted, and it is
likely that some change in the management of IPF has
occurred since (this will be evaluated in a follow-up
survey).
A comparison with the results of a survey of 272 aca-
demic pulmonologists conducted in 2006 in the USA [14]
shows that a similar proportion of pulmonologists pre-
scribed a pharmacological therapy to their IPF patients (73%
in France vs. 77% in the US), with little consensus regarding
modalities of management, as in the current survey. The
incorporation in the 2011 international guidelines of clinical
studies suggesting a possible efficacy of certain therapies
might explain these differences. However, corticosteroids
were more frequently prescribed by the French pulmonol-
ogists. From the US survey data, it can be inferred that
corticosteroid-based therapies were prescribed by 39% of
the respondents [14], compared with 49% in our survey. This
observation suggests that community respiratory physiciansmay need further education and regular updates regarding
the management of IPF. Comparison with older surveys
[15,16] is limited due to major changes in the definition of
IPF and in its diagnosis and management over the last
decades.
However, it must be stressed that 67% of respiratory
physicians involved in IPF were aware of the 2011 interna-
tional guidelines, and 84% of them considered the guide-
lines appropriate for practice. In a previous survey of 6443
pulmonary medicine board-certified fellows of the Amer-
ican College of Chest Physicians [17], 72% of all respondents
were familiar with the ATS/ERS consensus statement and
only 63% of them considered it clinically useful. This may
reflect an improved suitability between the documents
published in 2000 [18] and 2011 [2], as well as differences
related to the countries surveyed (namely, the USA and
France). Critical comments regarding the recommendations
and the need for updates have been published [19]. How-
ever, elucidating the reasons for the underlying insufficient
suitability of current guidelines and how this may have
influenced IPF management by physicians who expressed
this opinion is beyond the scope of this survey.
This survey has a number of limitations that must be
taken into account when interpreting its results. Forty-
eight percent of pulmonologists responded to the initial
question asking whether they were following up at least
one patient with IPF. This can be considered as a high
response rate, comparing favourably with a prior survey
with a response rate of 13% [17], yet pulmonogists partici-
pating to the present survey represented only 20% of all
French pulmonologists, i.e. a rate not high enough to make
use of the data reported here to write a comprehensive
description of IPF diagnosis and management in France. It
might be that the majority of non-responders were not
motivated because they did not have to deal with IPF pa-
tients, but this is only speculative. Calculated incidence
and prevalence were rough estimates, and the present
survey should not be seen as a valid epidemiologic study.
Furthermore, the results of the present survey may not
apply to other European countries, in which organisation of
care, national guidelines, and drug availability may vary. As
with any survey, ours relied on a self-report method of data
collection. It cannot be excluded that patients followed up
by several physicians in several care settings may have been
counted twice. In addition, imaging and pathology data
were not centrally reviewed.
Overall, this survey should be considered as giving a
broad picture, from which emerge several noteworthy
trends and current practice patterns for the diagnosis and
management of IPF in France. One major conclusion is that,
despite correct awareness of international IPF guidelines by
a majority of respiratory physicians, modalities of multi-
disciplinary discussion and of early diagnosis need to be
improved through care networks to be developed by the
expert centres. This survey has thus highlighted priorities
and needs for the improvement of the care of patients with
IPF.
The need to facilitate early diagnosis of the disease is
illustrated by a survey of 45 IPF patients from 5 European
countries [20], in which the reported time from initial
presentation to confirmed diagnosis of IPF ranged from <1
week to 12 years (median: 1.5 years); 55% of patients
Management of IPF in France 201reported consulting at least 3 physicians before receiving
an IPF diagnosis. In another prospective study of 129 adults
[21], the delay in diagnosing IPF was evaluated as 2.2 years
(interquartile range 1.0e3.8 years), with delayed access to
a tertiary care centre being associated with a higher risk of
death, independent of disease severity. As prompt treat-
ment of IPF depends on early diagnosis, which is mandatory
in improving the long-term outcome of this condition, we
recently argued that this may be achieved through more
attention being paid by general physicians to fine “Velcro”
crackles at lung auscultation (triggering further investiga-
tion when present and especially HRCT of the chest), and
through the use of current large-scale lung cancer
screening strategies with low-dose HRCT in smokers for the
incidental detection of subclinical ILD, and especially early
IPF [22].
Major initiatives taken in France following this survey
included the development, according to the method pro-
posed by the Haute Autorite´ de Sante´ (HAS) and under the
leadership of the Reference and Competence Centres, of
national recommendations on the diagnosis and manage-
ment of IPF [23]. While being an update of the international
recommendations of 2011, this expert consensus will also
aim to meet the needs expressed by French pulmonologists
for clear and practical diagnostic criteria and treatment
recommendations and summary. A tool for the multidisci-
plinary discussion has been made freely available to pul-
monologists caring for patients with IPF (http://www.splf.
fr/s/spip.php?article2225), educational meetings on IPF
have been held at the national and regional levels, and a
project has been initiated to organise care networks across
the French regions. Future studies will be needed to eval-
uate the impact on IPF management of the initiatives listed
above, and further surveys will be conducted once the re-
sults of several large clinical trials that are currently
ongoing worldwide will have been made available.
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